The effect of augmentin on sputum beta-lactamase activity in patients with cystic fibrosis.
D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002969:Clavulanic Acids / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications* / Q000201:enzymology; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006192:Haemophilus Infections / Q000150:complications / Q000188:drug therapy*; D006193:Haemophilus influenzae; D006801:Humans; D008297:Male; D013183:Sputum / Q000187:drug effects / Q000201:enzymology*; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D004338:Drug Combinations; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D001618:beta-Lactamases